Eli Lilly Alzheimer’s drug fails prevention study



Eli Lilly and Company stated on Wednesday that its older-generation drug solanezumab failed to slow the progression of cognitive decline due to Alzheimer’s disease in patients prior to the onset o…
About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento